Picard Medical Highlights Successful Heart Transplant Case Using Total Artificial Heart
Picard Medical, parent company of SynCardia Systems, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, highlighted a case reported by UCSF Health in which a patient in his twenties with advanced biventricular heart failure was successfully bridged to heart transplantation using the SynCardia Total Artificial Heart. The patient, a male in his twenties, received the SynCardia Total Artificial Heart on November 15, 2025 to restore full circulatory support while awaiting a donor heart. After 119 days of support with the device, the patient underwent a successful heart transplant on March 14, 2026. This case represents the second of five patients at UCSF Health who have been successfully bridged to transplantation using the SynCardia Total Artificial Heart.
